RE:RE:RE:A must watch PMX presentation by Dr. KellumRe upward valuation
The problem is there is currently no statistical basis for quantifying the revenue potential for these groups mentioned in Italy ( and here many times)
- Endotoxemuc, non culturable bacteria
- Covid patients suffering from gut dysbiosis and endotoxemia
- >.9 EAA patients that are effectively " under dosed" within current restrictive RCT parameters
Yet
my suspicion is that the buyer of PMX Rights for NA , knows that they are potentially very lucrative paths to pursue with add on studies once PMX is approved. If prospective buyers don't, they should.
perhaps EDEN is designed to shed some light on one or more of these areas of opportunity.
Collectively, I would say that they have the potential to double PMX revenues in the future. But that's just my guess.
MM